NEWRON PHARMA N/ IT0004147952 /
2024-04-26 5:31:30 PM | Chg. +0.590 | Volume | Bid5:40:00 PM | Ask5:40:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
7.280CHF | +8.82% | 59,318 Turnover: 423,204.190 |
-Bid Size: 25 | 7.280Ask Size: 998 | 129.91 mill.CHF | - | - |
Fundamentals
FY 2023 | Growth (1Y) | |
---|---|---|
Per Share | ||
Earnings per Share: | -0.91 EUR | -7.14% |
EPS Diluted: | - EUR | -7.14% |
Revenues per Share: | 0.51 EUR | 48.62% |
Book Value per Share: | -1.68 EUR | 113.17% |
Cash Flow per Share: | -0.57 EUR | -8.58% |
Dividend per Share: | - EUR | - |
Total | in mill. | |
Revenues: | 9.06 EUR | 48.62% |
Net Income: | -16.22 EUR | -7.25% |
Operating Cash Flow: | -10.14 EUR | - |
Cash and Cash Equivalents: | 6.34 EUR | - |
Valuation Ratios
Current | Latest FY* | |
---|---|---|
P/E Ratio: | - | - |
P/S Ratio: | 14.67 | 11.03 |
P/BV ratio: | -4.44 | -3.34 |
P/CF Ratio: | -13.10 | -9.86 |
PEG: | 1.15 | - |
Earnings Yield: | -12.22% | -16.25% |
Dividend Yield: | - | - |
Market Capitalization | ||
Market Capitalization: | 129.91 mill. CHF | 92.54 mill. CHF |
Free Float Market Cap.: | - CHF | - CHF |
Market Cap. / Employee: | - CHF | - CHF |
Shares Outstanding: | 17.85 mill. |
Profitability
Gross Profit Margin: | - |
EBIT Margin: | -128.40% |
Net Profit Margin: | -179.13% |
Return on Equity: | - |
Return on Assets: | -62.72% |
Financial Strength
Liquidity I / Cash Ratio: | 21.91% |
Liquidity II / Quick Ratio: | 46.29% |
Liquidity III / Current Ratio: | 67.94% |
Debt / Equity Ratio: | - |
Dynam. Debt / Equity Ratio: | -550.04% |
Efficiency
Employees: | - |
Personal Expenses / Employee: | - EUR |
Revenues / Employee: | - EUR |
Net Income / Employee: | - EUR |
Total Assets / Employee: | - EUR |
* Fiscal Year End: | 2023-12-31 |
Accounting Standard: | IFRS |
Currency: | EUR |